PTO/SB/21 (07-06)

	us	PTO/SB/21 (0/-0 Approved for use through 09/30/2008, OMB 0651-00. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC	
Under the Paperwork Reduction Act of 1995, no	o persons are required to respond to a co	collection of information unless it displays a valid OMB control number	
OIPE		10/748,658	
O ARANSMITTAL	Filing Date	December 31, 2003	
SEP 2 9 2006 TORM	First Named Inventor	Mathiesen, facob	
SEI " B	Art Unit	3767	
(to be use all correspondence after initial filin	Examiner Name	Gray, Phillip A.	
Total Number of Pages in This Submission	7 Attorney Docket Number	GTI-5001-CP	
	ENCLOSURES (Check a	il that apply)	
Fee Transmittal Form	Drawing(s)	After Allowance Communication to To	
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences	
Amendment/Reply [Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After Final	Petition to Convert to a Provisional Application	Proprietary Information	
	Power of Attorney, Revocati Change of Correspondence		
Affidavits/declaration(s)	Other Enclosure(s) (please Identify		
Extension of Time Request	Terminal Disclaimer	below):	
Express Abandonment Request	* Supp Transmittal (1 page) * Supp IDS Statement (2 pages)		
Information Disclosure Statement	CD, Number of CD(s)	* Supp SB/08 Form (1 page)	
	Landscape Table on C	* Reference (1 item) * Return Postcard (1 item)	
Certified Copy of Priority Document(s)	Remarks		
Reply to Missing Parts/			
Incomplete Application			
Reply to Missing Parts under 37 CFR 1.52 or 1.53			
under 57 67 K 1.52 67 1.55			
- CIONATA	IDE OF ARRIVOANT ATTO	DRIEV OR ACTUA	
Firm Name	JRE OF APPLICANT, ATTO	DRNEY, OR AGENT	
BioTechnology Law Group	<u> </u>		
Signature Mark M. Co.	while		
Printed name Daniel M. Chambers			
Date Sandaro	2006	Reg. No. 34,561	
CEF	RTJFIĆATE OF TRANSMISS	SION/MAILING	
I hereby certify that this correspondence is being sufficient postage as first class mail in an enwel the date shown below:	ng facsimile transmitted to the USP lope addressed to: Commissioner for	TO or deposited with the United States Postal Service with for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on	
Signature / //dust.	1 Menter-		
Typed or printed name Daniel M. Chamber	s	Date 1 1 201 201	

This collection of information is required by 3T CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is proversed by 3 U.S. C. 22 and 37 CFR 1.11 and 11.4. This collection is estimated to 2 bottomptes incidential gathering, preparing, and submitting the completed application from to the USPTO. Time well very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this butlene, should be sent to the Chief Information Officer, U.S. Patient and Tademark Office, U.S. Depart and Tademark Office, U.S. Depart and Tademark Office, U.S. Depart and Supplet Science (1) Commission of Commerce, P.O. Box 1450, Alexandria, V.A. 22313-1450. DN OT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND OT: Commission of For Patients, P.O. Box 1450, Alexandria, V.A. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mathiesen, Iacob Examiner:

Gray, Phillip A

Serial No.:

Group Art Unit:

3767

Filed:

December 31, 2003

10/748.658

Docket:

GTI-5001-CP

Title:

Electroporation Device and Injection Apparatus

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (1)

Mail Stop: AMENDMENT Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir/Madam:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed material is brought to the attention of the Examiner for consideration in connection with the above-identified patent application.

Applicants respectfully request that the enclosed Supplemental Information Disclosure Statement be entered, and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8:

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop: AMENDMENT, Commissioner of Patents. P.O.

Box 1450, Alexandria, VA 22313-1450

Name

Also, Applicants respectfully request that in patent application USSN 10/612,304, filed July 3, 2003, the Information Disclosure Statement, filed January 8, 2004, be incorporated and considered as part of the present application. As provided in 37 C.F.R. §1.98(d), copies of the documents listed the Information Disclosure Statement, except for EP 0460650, herein attached, are not being provided since they were previously cited by or submitted to the Patent Office in USSN. 10/612,304.

The listed document is being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits.

If any fees are due, please contact the undersigned attorney at (858) 350-9690.

The Examiner is invited to contact the Applicants' Representative at (858) 350-9690 if there are any questions regarding this communication.

Respectfully submitted

Reg. No. 34,561

BioTechnology Law Group 527 N. Highway 101, Suite E Solana Beach, CA 92075-1173 Telephone: 858 350-9690 Facsimile: 858 350-9691

dan@biotechnologylawgroup.com

Substitute for form 14490PTO INFORMATION DISCLOSURE STATEMENT BY ARP ECANT (Use as many sheets as pro-pany)

SEP 2 9 1005

Sheet 1 of 1

ider the Peperwork Reduction Act of 1995, no persons are: [Complete if Known	OS Pricer & Heatening Other U.S. DEPORTED TO CONTRICED required to respond to a collection of information united it contains a vol.d OMB control number
Application Number	10/748,658
Filing Date	December 31, 2003
First Named Inventor	Mathiesen, Iacob
Group Art Unit	3767
Examiner Name	Gray, Phillip A
Attorney Docket No.	GTI-5001-CP

Examiner initials *	Cite No.1	USP Document Number	Issued Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines,Where Relevant Passages or Relevant Figures Appear
	A1.	4,882,127	21 Nov 1989	Rosenthal et al	
	A2.	4,341,735	27 Jul 1982	Seifried	
-	A3.	3,645,692	29 Feb 1972	Stork et al	

		FORE	IGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines, Where Relevant Passages or Relevant Figures Appear	T²
	A4.	WO 98/43702	08 Oct 1998	Mathiesen, Iacob		
	A5.	WO 96/39226 A	12 Dec 1996	Genetronics, Inc.		
	A6.	WO 83/04309	12 Aug 1983	Ackermann et al		
	A7.	EP 0693951 B1	26 Aug 1998	Centre National De La Recherche Scientifique		
	A8.	EP 0460650 A3	12 Nov 1991	Labsystems OY		

Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item				
A9.	Chastain, M. et al., "Antigen levels and antibody titers after DNA vaccination," Journal of Pharmaceutical Science 90(4):474-484 (2001)			
A10.	Sanes, J. R., et al., "Selective expression of an acetylcholine receptor-tacZ transgene in synaptic nuclei of adult muscle fibers," <i>Development</i> 113:1181-1191 (1991)			
	Cite No 1	No ' (took, magazine, Journel, serial, symposium, catalog, etc.), date, page(a), volumé-lasúe númber(s), publisher, city, ander country where published. A9. Chastain, M. et al., "Antigen levels and antibody titers after DNA vaccination," Journal of Pharmaceutical Science 90(4):474-484 (2001) Sanes, J. R., et al., "Selective expression of an acetylcholine receptor-lacZ transgene in synaptic nuclei of adult muscle fibers," Development 113:1181-1191		

EXAMINER	/Phillip Gray/	DATE CONSIDERED	03/27/2009